1A Stock Chart & Stats
€102.45
€0.52(0.39%)
At close: 4:00 PM EST
€102.45
€0.52(0.39%)
Day’s Range― - ―
52-Week Range€55.00 - €188.00
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
€32.25B
Enterprise Value€36.67B
Total Cash (Recent Filing)€1.81B
Total Debt (Recent Filing)€3.35B
Price to Earnings (P/E)26.2
Beta0.63
Next Earnings
Aug 18, 2026EPS Estimate
1.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.99
Shares Outstanding282,431,950
10 Day Avg. Volume6
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio9.44
Price to Book (P/B)6.14
Price to Sales (P/S)5.96
P/FCF Ratio35.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€158.42Price Target Upside54.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)5.29
Revenue Forecast (FY)€6.50B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & ServicesAgilent’s mix of capital equipment plus recurring consumables, reagents, software and services builds durable, high-frequency revenue from an expanding installed base. This recurring stream improves revenue visibility, supports gross-margin stability and cushions cyclicality tied to one-time instrument sales over the next 2–6 months.
Margin Expansion And Pricing PowerConsistent margin expansion—driven by realized pricing (Ignite ~200 bps), manufacturing overhead reductions and product mix—signals structural pricing power and operational leverage. If management sustains pricing and productivity, margins should continue to support durable profitability despite macro pressures.
Healthy Free Cash Flow And Balance-sheet FlexibilityRobust FCF generation and improving leverage provide long-term financial flexibility to fund R&D, targeted M&A, dividends and buybacks while maintaining capex. Strong cash conversion supports strategic investments and cushions the business against short-term demand swings or higher funding costs.
Bears Say
China End-market ExposureMeaningful exposure to China leaves growth vulnerable to funding timing, policy shifts and local demand cycles. Prolonged weakness or delayed stimulus can materially depress instrument orders and consumables consumption, creating persistent headwinds to organic growth and near-term guidance conversion.
Margin Pressure Vs. Prior YearsAlthough recent quarters showed margin improvement, underlying gross-margin pressure versus historical peaks indicates structural cost or mix challenges. If pricing and productivity gains prove temporary, margins and long-term earnings leverage could be constrained, reducing sustainable profitability.
Weaker Operating Cash ConversionReduced cash conversion implies working-capital timing or collection stresses, lowering the quality of reported earnings. Persistent weakness here could limit free-cash-flow predictability, constrain reinvestment or raise refinancing risk if macro conditions tighten, harming long-term financial flexibility.
Agilent News
1A FAQ
What was Agilent Technologies’s price range in the past 12 months?
Agilent Technologies lowest stock price was €55.00 and its highest was €188.00 in the past 12 months.
What is Agilent Technologies’s market cap?
Agilent Technologies’s market cap is €32.25B.
When is Agilent Technologies’s upcoming earnings report date?
Agilent Technologies’s upcoming earnings report date is Aug 18, 2026 which is in 42 days.
How were Agilent Technologies’s earnings last quarter?
Agilent Technologies released its earnings results on May 27, 2026. The company reported €1.302 earnings per share for the quarter, beating the consensus estimate of €1.23 by €0.072.
Is Agilent Technologies overvalued?
According to Wall Street analysts Agilent Technologies’s price is currently Undervalued.
Does Agilent Technologies pay dividends?
Agilent Technologies does not currently pay dividends.
What is Agilent Technologies’s EPS estimate?
Agilent Technologies’s EPS estimate is 1.3.
How many shares outstanding does Agilent Technologies have?
Agilent Technologies has 282,431,950 shares outstanding.
What happened to Agilent Technologies’s price movement after its last earnings report?
Agilent Technologies reported an EPS of €1.302 in its last earnings report, beating expectations of €1.23. Following the earnings report the stock price went up 16.791%.
Which hedge fund is a major shareholder of Agilent Technologies?
Currently, no hedge funds are holding shares in IT:1A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agilent Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€158.42 (54.63% Upside)
€158.42 (54.63% Upside)
Blogger Sentiment
Bullish
IT:1A Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.18%
12-Months-Change
Fundamentals
Return on Equity
20.84%
Trailing 12-Months
Asset Growth
7.46%
Trailing 12-Months
Company Description
Agilent Technologies
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
1A Company Deck
1A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operational and financial performance: revenue, margins, and EPS all beat expectations, management raised full‑year guidance, and multiple indicators (instrument orders, segment outperformance, pricing, supply chain resilience and product innovation) point to durable momentum. Near-term challenges include China softness, food and academia/government weakness, and inflationary/geopolitical cost pressures that add uncertainty. On balance the positive operational wins and upgraded guidance outweigh the cited headwinds.View all IT:1A earnings summaries1A Revenue Breakdown
39.23% Life Sciences and Diagnostics Markets
41.85% Agilent CrossLab
18.91% Applied Markets

1A Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€158.42
▲(54.63% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Options Prices
Currently, No data available
---









